KR20050084184A - 신규한 쿠마린 아미드 유도체와 그 제조방법, 약제학적조성물과 용도 - Google Patents
신규한 쿠마린 아미드 유도체와 그 제조방법, 약제학적조성물과 용도 Download PDFInfo
- Publication number
- KR20050084184A KR20050084184A KR1020057010241A KR20057010241A KR20050084184A KR 20050084184 A KR20050084184 A KR 20050084184A KR 1020057010241 A KR1020057010241 A KR 1020057010241A KR 20057010241 A KR20057010241 A KR 20057010241A KR 20050084184 A KR20050084184 A KR 20050084184A
- Authority
- KR
- South Korea
- Prior art keywords
- och
- phenylamidocarbonyl
- group
- amidosulfonyl
- compound
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims abstract description 43
- 229940079593 drug Drugs 0.000 title claims abstract description 36
- 239000000203 mixture Substances 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title claims description 13
- 150000001875 compounds Chemical class 0.000 claims abstract description 183
- 238000000034 method Methods 0.000 claims abstract description 57
- 238000011282 treatment Methods 0.000 claims abstract description 17
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 8
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 6
- 230000003902 lesion Effects 0.000 claims abstract description 3
- 208000026106 cerebrovascular disease Diseases 0.000 claims abstract 3
- 229910004013 NO 2 Inorganic materials 0.000 claims description 138
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 130
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 100
- -1 Komarin derivative compounds Chemical class 0.000 claims description 45
- 229910052739 hydrogen Inorganic materials 0.000 claims description 32
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 22
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 19
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 16
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 15
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 15
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 claims description 14
- 208000020832 chronic kidney disease Diseases 0.000 claims description 12
- 102000005862 Angiotensin II Human genes 0.000 claims description 11
- 101800000733 Angiotensin-2 Proteins 0.000 claims description 11
- 206010020772 Hypertension Diseases 0.000 claims description 11
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 claims description 11
- 125000003545 alkoxy group Chemical group 0.000 claims description 11
- 229950006323 angiotensin ii Drugs 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 229910052736 halogen Inorganic materials 0.000 claims description 9
- 150000002367 halogens Chemical class 0.000 claims description 9
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 8
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 7
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- 150000002148 esters Chemical class 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 6
- 239000000194 fatty acid Substances 0.000 claims description 6
- 229930195729 fatty acid Natural products 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 6
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 238000012377 drug delivery Methods 0.000 claims description 5
- 150000004665 fatty acids Chemical class 0.000 claims description 5
- 239000003112 inhibitor Substances 0.000 claims description 5
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 claims description 5
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims description 4
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 4
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 claims description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 4
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 claims description 4
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 239000000376 reactant Substances 0.000 claims description 4
- 210000004556 brain Anatomy 0.000 claims description 3
- 229910052794 bromium Inorganic materials 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 230000000747 cardiac effect Effects 0.000 claims description 3
- 239000003054 catalyst Substances 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- 125000004185 ester group Chemical group 0.000 claims description 3
- 229910052740 iodine Inorganic materials 0.000 claims description 3
- 238000006467 substitution reaction Methods 0.000 claims description 3
- 150000003512 tertiary amines Chemical class 0.000 claims description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 claims description 2
- GEFDYGOYVXEKBE-UHFFFAOYSA-N 2-oxochromene-6-carboxylic acid Chemical compound O1C(=O)C=CC2=CC(C(=O)O)=CC=C21 GEFDYGOYVXEKBE-UHFFFAOYSA-N 0.000 claims description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 238000009833 condensation Methods 0.000 claims description 2
- 230000005494 condensation Effects 0.000 claims description 2
- 238000013270 controlled release Methods 0.000 claims description 2
- 239000010419 fine particle Substances 0.000 claims description 2
- 239000003102 growth factor Substances 0.000 claims description 2
- 229940073020 nitrol Drugs 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 238000013268 sustained release Methods 0.000 claims description 2
- 239000012730 sustained-release form Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical class NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims 3
- 208000006011 Stroke Diseases 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 claims 1
- 206010011084 Coronary artery embolism Diseases 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 238000007112 amidation reaction Methods 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 238000006482 condensation reaction Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 150000002429 hydrazines Chemical class 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 201000010849 intracranial embolism Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 239000003960 organic solvent Substances 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 238000007363 ring formation reaction Methods 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 abstract description 22
- 206010030113 Oedema Diseases 0.000 abstract description 3
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 125000000332 coumarinyl group Chemical class O1C(=O)C(=CC2=CC=CC=C12)* 0.000 abstract 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 54
- 230000015572 biosynthetic process Effects 0.000 description 50
- 238000003786 synthesis reaction Methods 0.000 description 50
- 238000005160 1H NMR spectroscopy Methods 0.000 description 45
- 238000000921 elemental analysis Methods 0.000 description 31
- 235000001671 coumarin Nutrition 0.000 description 29
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 26
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 26
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 20
- 229960000956 coumarin Drugs 0.000 description 17
- 241000700159 Rattus Species 0.000 description 16
- 150000004775 coumarins Chemical class 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 16
- 238000004364 calculation method Methods 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 201000010099 disease Diseases 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 208000017169 kidney disease Diseases 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- 235000002639 sodium chloride Nutrition 0.000 description 11
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 235000019441 ethanol Nutrition 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 9
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 8
- 239000002083 C09CA01 - Losartan Substances 0.000 description 8
- 229960004909 aminosalicylic acid Drugs 0.000 description 8
- 229960004773 losartan Drugs 0.000 description 8
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 8
- 229960004963 mesalazine Drugs 0.000 description 8
- 208000001647 Renal Insufficiency Diseases 0.000 description 7
- 229960004530 benazepril Drugs 0.000 description 7
- MTZQAGJQAFMTAQ-UHFFFAOYSA-N benzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1 MTZQAGJQAFMTAQ-UHFFFAOYSA-N 0.000 description 7
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 7
- 201000006370 kidney failure Diseases 0.000 description 7
- 230000007170 pathology Effects 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000001356 surgical procedure Methods 0.000 description 7
- ODRDTKMYQDXVGG-UHFFFAOYSA-N 8-methoxychromen-2-one Chemical compound C1=CC(=O)OC2=C1C=CC=C2OC ODRDTKMYQDXVGG-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- VEEGNDSSWAOLFN-UHFFFAOYSA-N 7-methoxy-2-oxochromene-3-carboxylic acid Chemical compound C1=C(C(O)=O)C(=O)OC2=CC(OC)=CC=C21 VEEGNDSSWAOLFN-UHFFFAOYSA-N 0.000 description 5
- 101150051135 Mink1 gene Proteins 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 241000772415 Neovison vison Species 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 210000002919 epithelial cell Anatomy 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- BRBKOPJOKNSWSG-UHFFFAOYSA-N sulfaguanidine Chemical compound NC(=N)NS(=O)(=O)C1=CC=C(N)C=C1 BRBKOPJOKNSWSG-UHFFFAOYSA-N 0.000 description 5
- 229960004257 sulfaguanidine Drugs 0.000 description 5
- XMQOBGDXGQSRID-UHFFFAOYSA-N 2-oxochromene-3-carboxamide Chemical class C1=CC=C2OC(=O)C(C(=O)N)=CC2=C1 XMQOBGDXGQSRID-UHFFFAOYSA-N 0.000 description 4
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 4
- FDNPBKXFZNKRFY-UHFFFAOYSA-N 7-hydroxy-8-nitrochromen-2-one Chemical compound C1=CC(=O)OC2=C([N+]([O-])=O)C(O)=CC=C21 FDNPBKXFZNKRFY-UHFFFAOYSA-N 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 230000001093 anti-cancer Effects 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 235000001727 glucose Nutrition 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 238000006396 nitration reaction Methods 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000008085 renal dysfunction Effects 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- 208000019553 vascular disease Diseases 0.000 description 4
- SYMHUWGEDWKHKT-UHFFFAOYSA-N 6-chloro-7-methoxy-2-oxochromene-3-carboxylic acid Chemical compound O1C(=O)C(C(O)=O)=CC2=C1C=C(OC)C(Cl)=C2 SYMHUWGEDWKHKT-UHFFFAOYSA-N 0.000 description 3
- 206010016654 Fibrosis Diseases 0.000 description 3
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 3
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001647 drug administration Methods 0.000 description 3
- 230000004761 fibrosis Effects 0.000 description 3
- 230000001434 glomerular Effects 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000003169 placental effect Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- 210000001635 urinary tract Anatomy 0.000 description 3
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 2
- STPKWKPURVSAJF-LJEWAXOPSA-N (4r,5r)-5-[4-[[4-(1-aza-4-azoniabicyclo[2.2.2]octan-4-ylmethyl)phenyl]methoxy]phenyl]-3,3-dibutyl-7-(dimethylamino)-1,1-dioxo-4,5-dihydro-2h-1$l^{6}-benzothiepin-4-ol Chemical compound O[C@H]1C(CCCC)(CCCC)CS(=O)(=O)C2=CC=C(N(C)C)C=C2[C@H]1C(C=C1)=CC=C1OCC(C=C1)=CC=C1C[N+]1(CC2)CCN2CC1 STPKWKPURVSAJF-LJEWAXOPSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- WGFNXGPBPIJYLI-UHFFFAOYSA-N 2,6-difluoro-3-[(3-fluorophenyl)sulfonylamino]-n-(3-methoxy-1h-pyrazolo[3,4-b]pyridin-5-yl)benzamide Chemical compound C1=C2C(OC)=NNC2=NC=C1NC(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=CC(F)=C1 WGFNXGPBPIJYLI-UHFFFAOYSA-N 0.000 description 2
- QEBYEVQKHRUYPE-UHFFFAOYSA-N 2-(2-chlorophenyl)-5-[(1-methylpyrazol-3-yl)methyl]-4-[[methyl(pyridin-3-ylmethyl)amino]methyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound C1=CN(C)N=C1CN1C(=O)C=C2NN(C=3C(=CC=CC=3)Cl)C(=O)C2=C1CN(C)CC1=CC=CN=C1 QEBYEVQKHRUYPE-UHFFFAOYSA-N 0.000 description 2
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 2
- XKGDSQJAWPPBHI-UHFFFAOYSA-N 3-(fluoromethyl)aniline Chemical compound NC1=CC=CC(CF)=C1 XKGDSQJAWPPBHI-UHFFFAOYSA-N 0.000 description 2
- XFDUHJPVQKIXHO-UHFFFAOYSA-N 3-aminobenzoic acid Chemical compound NC1=CC=CC(C(O)=O)=C1 XFDUHJPVQKIXHO-UHFFFAOYSA-N 0.000 description 2
- WYFCZWSWFGJODV-MIANJLSGSA-N 4-[[(1s)-2-[(e)-3-[3-chloro-2-fluoro-6-(tetrazol-1-yl)phenyl]prop-2-enoyl]-5-(4-methyl-2-oxopiperazin-1-yl)-3,4-dihydro-1h-isoquinoline-1-carbonyl]amino]benzoic acid Chemical compound O=C1CN(C)CCN1C1=CC=CC2=C1CCN(C(=O)\C=C\C=1C(=CC=C(Cl)C=1F)N1N=NN=C1)[C@@H]2C(=O)NC1=CC=C(C(O)=O)C=C1 WYFCZWSWFGJODV-MIANJLSGSA-N 0.000 description 2
- PLIKAWJENQZMHA-UHFFFAOYSA-N 4-aminophenol Chemical compound NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 description 2
- HGNLBYVUZVEAJB-UHFFFAOYSA-N 6-ethyl-7-methoxy-2-oxochromene-3-carboxylic acid Chemical compound C1=C(C(O)=O)C(=O)OC2=C1C=C(CC)C(OC)=C2 HGNLBYVUZVEAJB-UHFFFAOYSA-N 0.000 description 2
- IGDXBFZUBGQGMM-UHFFFAOYSA-N 7,8-dimethoxy-2-oxochromene-3-carboxylic acid Chemical compound C1=C(C(O)=O)C(=O)OC2=C(OC)C(OC)=CC=C21 IGDXBFZUBGQGMM-UHFFFAOYSA-N 0.000 description 2
- MDFFBJOZHRYEPX-UHFFFAOYSA-N 7-hydroxy-8-methoxy-6-nitro-2-oxochromene-3-carboxylic acid Chemical compound C(=O)(O)C=1C(OC2=C(C(=C(C=C2C1)[N+](=O)[O-])O)OC)=O MDFFBJOZHRYEPX-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- JQUCWIWWWKZNCS-LESHARBVSA-N C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F Chemical compound C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F JQUCWIWWWKZNCS-LESHARBVSA-N 0.000 description 2
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- LVDRREOUMKACNJ-BKMJKUGQSA-N N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)N[C@H]1CCC(=O)N([C@@H]1c1ccc(Cl)cc1)c1ccc2c(C)cc(=O)n(C)c2c1 LVDRREOUMKACNJ-BKMJKUGQSA-N 0.000 description 2
- AVYVHIKSFXVDBG-UHFFFAOYSA-N N-benzyl-N-hydroxy-2,2-dimethylbutanamide Chemical compound C(C1=CC=CC=C1)N(C(C(CC)(C)C)=O)O AVYVHIKSFXVDBG-UHFFFAOYSA-N 0.000 description 2
- 108010094028 Prothrombin Proteins 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 208000037386 Typhoid Diseases 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- 229960004050 aminobenzoic acid Drugs 0.000 description 2
- 229940053202 antiepileptics carboxamide derivative Drugs 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 239000012148 binding buffer Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 208000033679 diabetic kidney disease Diseases 0.000 description 2
- 235000013681 dietary sucrose Nutrition 0.000 description 2
- GCSAXWHQFYOIFE-UHFFFAOYSA-N dipyridin-2-yl carbonate Chemical compound C=1C=CC=NC=1OC(=O)OC1=CC=CC=N1 GCSAXWHQFYOIFE-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- GZQRFGMWDSAMBK-UHFFFAOYSA-N ethyl 6-chloro-7-hydroxy-8-nitro-2-oxochromene-3-carboxylate Chemical compound ClC1=C(O)C([N+]([O-])=O)=C2OC(=O)C(C(=O)OCC)=CC2=C1 GZQRFGMWDSAMBK-UHFFFAOYSA-N 0.000 description 2
- WUFKHIVDULQDLS-UHFFFAOYSA-N ethyl 6-ethyl-7-hydroxy-8-nitro-2-oxochromene-3-carboxylate Chemical compound CCC1=C(O)C([N+]([O-])=O)=C2OC(=O)C(C(=O)OCC)=CC2=C1 WUFKHIVDULQDLS-UHFFFAOYSA-N 0.000 description 2
- JXAIAZYGEYXKGM-UHFFFAOYSA-N ethyl 7,8-dimethoxy-6-nitro-2-oxochromene-3-carboxylate Chemical compound [O-][N+](=O)C1=C(OC)C(OC)=C2OC(=O)C(C(=O)OCC)=CC2=C1 JXAIAZYGEYXKGM-UHFFFAOYSA-N 0.000 description 2
- RYGZSTWNUXKZQM-UHFFFAOYSA-N ethyl 7-hydroxy-6,8-dinitro-2-oxochromene-3-carboxylate Chemical compound [O-][N+](=O)C1=C(O)C([N+]([O-])=O)=C2OC(=O)C(C(=O)OCC)=CC2=C1 RYGZSTWNUXKZQM-UHFFFAOYSA-N 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 206010061989 glomerulosclerosis Diseases 0.000 description 2
- 235000012907 honey Nutrition 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000008176 lyophilized powder Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 210000001589 microsome Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- DYGBNAYFDZEYBA-UHFFFAOYSA-N n-(cyclopropylmethyl)-2-[4-(4-methoxybenzoyl)piperidin-1-yl]-n-[(4-oxo-1,5,7,8-tetrahydropyrano[4,3-d]pyrimidin-2-yl)methyl]acetamide Chemical compound C1=CC(OC)=CC=C1C(=O)C1CCN(CC(=O)N(CC2CC2)CC=2NC(=O)C=3COCCC=3N=2)CC1 DYGBNAYFDZEYBA-UHFFFAOYSA-N 0.000 description 2
- 229940105631 nembutal Drugs 0.000 description 2
- 201000008383 nephritis Diseases 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000010695 polyglycol Substances 0.000 description 2
- 229920000151 polyglycol Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- YPFDHNVEDLHUCE-UHFFFAOYSA-N propane-1,3-diol Chemical compound OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 201000002793 renal fibrosis Diseases 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- GUAFOGOEJLSQBT-UHFFFAOYSA-N scoparone Chemical compound C1=CC(=O)OC2=C1C=C(OC)C(OC)=C2 GUAFOGOEJLSQBT-UHFFFAOYSA-N 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 2
- 229960004306 sulfadiazine Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229940099456 transforming growth factor beta 1 Drugs 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 201000008297 typhoid fever Diseases 0.000 description 2
- 208000026533 urinary bladder disease Diseases 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
- ACMLKANOGIVEPB-UHFFFAOYSA-N 2-oxo-2H-chromene-3-carboxylic acid Chemical class C1=CC=C2OC(=O)C(C(=O)O)=CC2=C1 ACMLKANOGIVEPB-UHFFFAOYSA-N 0.000 description 1
- CUMCMYMKECWGHO-UHFFFAOYSA-N 3-methyl-1,2-oxazole Chemical compound CC=1C=CON=1 CUMCMYMKECWGHO-UHFFFAOYSA-N 0.000 description 1
- RGUKYNXWOWSRET-UHFFFAOYSA-N 4-pyrrolidin-1-ylpyridine Chemical compound C1CCCN1C1=CC=NC=C1 RGUKYNXWOWSRET-UHFFFAOYSA-N 0.000 description 1
- SJMCEDFBJFYVPN-UHFFFAOYSA-N 6-bromo-7-methoxy-2-oxochromene-3-carboxylic acid Chemical compound O1C(=O)C(C(O)=O)=CC2=C1C=C(OC)C(Br)=C2 SJMCEDFBJFYVPN-UHFFFAOYSA-N 0.000 description 1
- IETDBZQIWIJQJG-UHFFFAOYSA-N 7-hydroxy-2-oxo-chromene-3-carboxylic acid ethyl ester Chemical compound C1=C(O)C=C2OC(=O)C(C(=O)OCC)=CC2=C1 IETDBZQIWIJQJG-UHFFFAOYSA-N 0.000 description 1
- OCDNOUQMKORPIY-UHFFFAOYSA-N 7-methoxy-8-methyl-2-oxochromene-3-carboxylic acid Chemical compound C1=C(C(O)=O)C(=O)OC2=C(C)C(OC)=CC=C21 OCDNOUQMKORPIY-UHFFFAOYSA-N 0.000 description 1
- ZIDKNYDLXMASDO-UHFFFAOYSA-N 7-methoxy-8-methyl-6-nitro-2-oxochromene-3-carboxylic acid Chemical compound O1C(=O)C(C(O)=O)=CC2=C1C(C)=C(OC)C([N+]([O-])=O)=C2 ZIDKNYDLXMASDO-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- XASOHFCUIQARJT-UHFFFAOYSA-N 8-methoxy-6-[7-(2-morpholin-4-ylethoxy)imidazo[1,2-a]pyridin-3-yl]-2-(2,2,2-trifluoroethyl)-3,4-dihydroisoquinolin-1-one Chemical compound C(N1C(=O)C2=C(OC)C=C(C=3N4C(=NC=3)C=C(C=C4)OCCN3CCOCC3)C=C2CC1)C(F)(F)F XASOHFCUIQARJT-UHFFFAOYSA-N 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 238000010953 Ames test Methods 0.000 description 1
- 231100000039 Ames test Toxicity 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- SCJNYBYSTCRPAO-LXBQGUBHSA-N CN(C)C\C=C\C(=O)NC1=CC=C(N=C1)C(=O)N[C@@]1(C)CCC[C@H](C1)NC1=NC(C2=CNC3=CC=CC=C23)=C(Cl)C=N1 Chemical compound CN(C)C\C=C\C(=O)NC1=CC=C(N=C1)C(=O)N[C@@]1(C)CCC[C@H](C1)NC1=NC(C2=CNC3=CC=CC=C23)=C(Cl)C=N1 SCJNYBYSTCRPAO-LXBQGUBHSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 208000026372 Congenital cystic kidney disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 208000022461 Glomerular disease Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 206010023421 Kidney fibrosis Diseases 0.000 description 1
- 241000282341 Mustela putorius furo Species 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 208000030331 Posterior urethral valve Diseases 0.000 description 1
- 206010037601 Pyelonephritis chronic Diseases 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- PJSFRIWCGOHTNF-UHFFFAOYSA-N Sulphormetoxin Chemical compound COC1=NC=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1OC PJSFRIWCGOHTNF-UHFFFAOYSA-N 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- BQODPTQLXVVEJG-UHFFFAOYSA-N [O].C=C Chemical group [O].C=C BQODPTQLXVVEJG-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000002862 amidating effect Effects 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- VEQOALNAAJBPNY-UHFFFAOYSA-N antipyrine Chemical compound CN1C(C)=CC(=O)N1C1=CC=CC=C1 VEQOALNAAJBPNY-UHFFFAOYSA-N 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- WARCRYXKINZHGQ-UHFFFAOYSA-N benzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1 WARCRYXKINZHGQ-UHFFFAOYSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000036782 biological activation Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 208000029162 bladder disease Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 201000006368 chronic pyelonephritis Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940125851 compound 27 Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000008259 diffuse glomerulonephritis Diseases 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- ZWHUCBMLKBXHCX-UHFFFAOYSA-N ethyl 6-chloro-7-hydroxy-2-oxochromene-3-carboxylate Chemical compound ClC1=C(O)C=C2OC(=O)C(C(=O)OCC)=CC2=C1 ZWHUCBMLKBXHCX-UHFFFAOYSA-N 0.000 description 1
- CQHYBYOLCKQVGO-UHFFFAOYSA-N ethyl 6-ethyl-7-methoxy-2-oxochromene-3-carboxylate Chemical compound C(C)OC(=O)C=1C(OC2=CC(=C(C=C2C1)CC)OC)=O CQHYBYOLCKQVGO-UHFFFAOYSA-N 0.000 description 1
- ZJXBBNRJRXIJPH-UHFFFAOYSA-N ethyl 7,8-dimethoxy-2-oxochromene-3-carboxylate Chemical compound C1=C(OC)C(OC)=C2OC(=O)C(C(=O)OCC)=CC2=C1 ZJXBBNRJRXIJPH-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000010944 ethyl methyl cellulose Nutrition 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 231100000852 glomerular disease Toxicity 0.000 description 1
- 229940015043 glyoxal Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 201000006334 interstitial nephritis Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229960003350 isoniazid Drugs 0.000 description 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 230000032630 lymph circulation Effects 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229920003087 methylethyl cellulose Polymers 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000000802 nitrating effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229960005222 phenazone Drugs 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 208000030761 polycystic kidney disease Diseases 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 201000008171 proliferative glomerulonephritis Diseases 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 206010038464 renal hypertension Diseases 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000009958 sewing Methods 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960004673 sulfadoxine Drugs 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 201000005060 thrombophlebitis Diseases 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- UOCLRXFKRLRMKV-UHFFFAOYSA-N trolnitrate phosphate Chemical compound OP(O)(O)=O.OP(O)(O)=O.[O-][N+](=O)OCCN(CCO[N+]([O-])=O)CCO[N+]([O-])=O UOCLRXFKRLRMKV-UHFFFAOYSA-N 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 201000009160 urethral calculus Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
- C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrane Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Description
실험용 화합물 기호(10ug/ml) | 26 | 92 | 73 | 7 | 2 |
밍크의 폐 상피세포의 세포성장 억제 작용율(%) | 70. 7 | 95. 0 | 15. 1 | 67. 1 | 27. 1 |
Claims (18)
- 하기 화학식 (I)로 표시되는 코마린 유도체 화합물:상기 식에서,R3는 H, 카르복실, 알킬옥시카르보닐, 5'-(페닐옥사디아졸-2')-일, 5'-(피리딜-4"-옥사디아졸-2'), , 또는 CONHR9로부터 선택되고, 여기서 R9는 C2-C8지방산, 벤즈옥스아미도, 이소니코틴아미도, 및 비치환 또는 일- 또는 다-치환의 페닐로 이루어진 군으로부터 선택된 것이고, 상기 치환기는 OH, C1-C8 알콕시기, CF3, 카르복실, 알킬옥시카르보닐기, OCH2CO2H, NO2, 할로겐, SO3H, 및 SO2NHR11로 이루어진 군에서 선택될 수 있으며, 그 중 R11은 H, 아미디노, 2"-티아졸일(thiazolyl), 3"-(5"-메틸이소옥사졸일), 2"-피리미디닐(pyrimidinyl), 2"-(4",6"-디메틸 피리미디닐), 및 4"-(5", 6"-디메톡시 피리미디닐)로 이루어진 군에서 선택된 것이고;R4는 H, 또는 CONHR10으로부터 선택된 것이며, 상기 R10은 C2-C8 지방산, 벤즈옥사미도, 이소니코틴아미도,및 비치환 또는 일- 혹은 다치환- 페닐에서 선택된 것이다. 벤젠 고리 위의 대치기는 OH, C1-C8 알콕시기, CF3, 카르복실, 에스테르기, OCH2CO2H, NO2, 할로겐, SO3H, SO2NHR12 일 수 있다. 그 중 R12는 상기 치환기는 OH, C1-C8 알콕시기, CF3, 카르복실, 알킬옥시카르보닐기, OCH2CO2H, NO2, 할로겐, SO3H, 및 SO2NHR11로 이루어진 군에서 선택될 수 있으며, 그 중 R11은 H, 아미디노, 2"-티아졸일(thiazolyl), 3"-(5"-메틸이소옥사졸일), 2"-피리미디닐(pyrimidinyl), 2"-(4",6"-디메틸 피리미디닐), 및 4"-(5", 6"-디메톡시 피리미디닐)로 이루어진 군에서 선택된 것이고;R5는 H, 또는 C1-C4의 알킬로부터 선택된 것이고;R6은 H, C1-C12의 알킬, 할로겐, NO2, 및 CONHR13로 이루어진 군으로부터 선택되고, 그 중 R13은 치환된 페닐기이고;R7은 H, OH, C1-C4 알킬, 알콕시기, 카르복시알킬렌옥시, 및 OCH2CONHR14으로부터 선택된 것이고, 그 중 R14는 비치환, 일- 또는 다치환 페닐기 중에서 선택된 것이고, 상기 치환기는 OH, OCH3, CF3, CO2H, CO2C2H5, 또는 NO2이고; 또한R8은 H, C1-C4 알킬 또는 알콕시기, 및 NO2로 이루어지는 군에서 선택된 것이다.
- 제1항에 있어서, 상기 화합물은 하기와 같이 표시되는 것을 특징으로 하는 화합물:R3은 H, COOH, CO2C2H5, 5'-(페닐옥사디아졸-2')-일, 5'-(피리딜-4"-옥사디아졸-2')-일, , 및 CONHR9중에서 선택된 것이고, 그 중 R9는 n-낙산(butyric acid), o-, m-, p-페놀기, o-, m-, p-카르복시페닐, o-, m-, p-알킬옥시카르보페닐, 메톡시페닐, m-카르복실메톡시페닐, 3'-히드록시-4'-카르복시페닐, 3'-살리실일(salicylyl), 4'-살리실일(salicylyl), m-CF3-페닐, 3'-CF3-4'-NO2-페닐, 2'-CO2H-4'-I-페닐, 이소니코틴아미도(isonicotinamido), 벤즈옥사미도(benzoxamido), 3'-카르복시-메틸렌옥시페닐, 4'-아미드설폰일(amidosulfonyl)페닐, 4'-구아니디노설폰일(guanidinosulfonyl)페닐, 4'-(2"-티아졸아미도설폰일thiazolamidosulfonyl)페닐, 4'-5"-[메틸이소옥사졸일(methylisooxazolyl)-3"-아미도설폰일(amidosulfonyl)]페닐, 4'-피리미디닐-2"-아미드설폰일(pyrimidinyl-2"-amidosulfonyl)페닐, 4'-[4",6"-디메틸피리미디닐(dimethylpyrimidinyl)-2"-아미도설폰일(amidosulfonyl)]페닐, 및 4'-(5",6"-디메톡시피리미디닐-4"-아미도설폰일)페닐로 이루어지는 군으로부터 선택된 것이고;R4는 H, 또는 CONHR10이고, 여기서 R10는 H, 4'-CO2H-페닐, 4'-CO2C2H5페닐, 및 3'-CF3-페닐로 이루어진 군으로부터 선택된 것이고;R5는 H, 또는 CH3이고;R6은 H, C2H5, n-C6H13, NO2, NH2, Cl, Br, 및 CONHR13로 이루어진 군으로부터 선택된 것이고, 여기서 R13은 4-카르복시페닐기 및 4'-에틸옥시카르보닐페닐로 이루어진 군에서 선택된 것이고;R7는 H, OH, CH3, OCH3, 및 OCH2CONHR14로 이루어진 군에서 선택된 것이고, 여기서 R14는 페닐, o-, m-, p-히드록시페닐, o-, m- ,p-카르복시페닐, 4'-에톡시카르보닐페닐, 3'-에톡시카르보닐(ethoxycarbonyl)페닐, 3'-트리플루오로메틸(trifluoromethyl)페닐, 3'-트리플루오로메틸-4-니트롤(nitro)페닐, 4'-메톡시페닐(methoxyphenyl), 4'-살리실일(salicylyl), 3'-살리실일(salicylyl)이고;R8은 H, CH3, OCH3, 및 NO2로 이루어진 군에서 선택된다.
- 제1항에 있어서, 상기 화학식 (I)가 하기의 화학식(Ia)로 표시되는 코마린 유도체 화합물인 것을 특징으로 하는 화합물:상기 식에서, R4, R5, R6, R7, 및 R8는 화학식 I은 청구항 1항에 정의된 바와 같고, R=(CH)3COOH, 로 표시된다.
- 제1항에 있어서, 상기 화학식 (I)가 하기의 화학식(Ib)로 표시되는 코마린 유도체 화합물인 것을 특징으로 하는 화합물:상기 식에서, R4, R5, R6, R7, 및 R8는 화학식 I에서 나타낸 바와 같고,R'2는 H, OH, 및 COOH로 이루어진 군에서 선택된 것이고;R'3은 H, OH, CO2H, CF3, 및 OCH2CO2H로 이루어진 군에서 선택된 것이고;R'4는 H, OH, CO2H, CO2Et, I, NO2, OCH3, SO3H, SO2NH2, SO2NH(C=NH)NH2, 으로부터 선택된 것이고;R'5 및 R'6은 각각 H이다.
- 제2항에 있어서, 상기 화합물중 R3, R4, R5, R6, R7, 및 R8은 각각 독립적으로 하기의 화합물로 이루어진 군에서 선택된 하나인 것을 특징으로 하는 화합물:R3=p-CO2H-페닐아미도카르보닐, R4=R5=R6=R8=H, R7=OCH3;R3=m-CO2H-페닐아미도카르보닐, R4=R5=R6=R8=H, R7=OCH3;R3=o-CO2H-페닐아미도카르보닐, R4=R5=R6=R8=H, R7=OCH3;R3=o-OH-페닐아미도카르보닐, R4=R5=R6=R8=H, R7=OCH3;R3=m-OH-페닐아미도카르보닐, R4=R5=R6=R8=H, R7=OCH3;R3=p-OH-페닐아미도카르보닐, R4=R5=R6=R8=H, R7=OCH3;R3=m-OH-p-CO2H-페닐아미도카르보닐, R4=R5= R6 =R8=H, R7=OCH3;R3=m-CO2H-p-OH-페닐아미도카르보닐, R4=R5= R6=R8=H, R7=OCH3;R3=o-CO2H-p-I-페닐아미도카르보닐, R4=R5=R6=R8=H, R7=OCH3;R3=4'-에톡시카르보페닐아미도카르보닐, R4=R5=R6=R8=H, R7=OCH3;R3=m-CF3-페닐아미도카르보닐, R4=R5=R6=R8=H, R7=OCH3;R3=m-CF3-p-NO2-페닐아미도카르보닐, R4=R5=R6=R8=H, R7=OCH3;R3=4'-아미도설포닐페닐아미도카르보닐, R4=R5=R6=R8=H, R7=OCH3;R3=4'-구아니디노설포닐페닐아미도카르보닐, R4=R5=R6=R8=H, R7=OCH3;R3=4'-(2"-티아졸아미도설포닐)페닐아미도카르보닐, R4=R5=R6=R8=H, R7=OCH3;R3=4'-(2"-피리미디닐아미도설포닐)페닐아미도카르보닐,R4=R5=R6=R8=H, R7=OCH3;R3=4'-[2"-(4",6"-디메틸피리미디닐아미도설포닐)]페닐아미도카르보닐,R4=R5=R6=R8=H, R7=OCH3;R3=4'-(5",6"-디메톡시피리미디닐-4"-아미도설포닐)페닐아미도카르보닐,R4=R5=R6=R8=H, R7=OCH3;R3=4'-(5"-메틸-이소옥사졸-3"-아미도설포닐)페닐아미도카르보닐,R4=R5=R6=R8=H, R7=OCH3;R3=p-OCH3-페닐아미도카르보닐, R4=R5=R6=R8=H, R7=OCH3;R3=p-SO3H-페닐아미도카르보닐, R4=R5=R6=R8=H, R7=OCH3;R3= p-CO2H-페닐아미도카르보닐, R4=R5=R8=H, R6=C2H5, R7=OCH3 ;R3=m-CO2H-페닐아미도카르보닐, R4=R5=R8=H, R6=C2H5, R7=OCH3 ;R3=o-CO2H-페닐아미도카르보닐, R4=R5=R8=H, R6=C2H5, R7=OCH3 ;R3=p-OH-페닐아미도카르보닐, R4=R5 =R8=H, R6=C2H5, R7=OCH3;R3=m-OH-p-CO2H-페닐아미도카르보닐, R4=R5=R8=H, R6=C2H5, R7=OCH3;R3=m-CO2H-p-OH-페닐아미도카르보닐, R4=R5=R8=H, R6=C2H5, R7=OCH3;R3=4'-에톡시카르보페닐아미도카르보닐, R4=R5=R8=H, R6=C2H5, R7=OCH3;R3=m-CF3-페닐아미도카르보닐, R4=R5=R8=H, R6=C2H5, R7=OCH3;R3=m-CF3-4-NO2-페닐아미도카르보닐, R4=R5=R8=H, R6=C2H5, R7=OCH3;R3=4'-아미도설포닐페닐아미도카르보닐, R4=R5=R8=H, R6= C2H5, R7=OCH3;R3=4'-구아니디노설포닐페닐아미도카르보닐,R4=R5=R8=H, R6=C2H5, R7=OCH3;R3=4'-(2"-티아졸아미도설포닐)페닐아미도카르보닐,R4=R5=R8=H, R6=C2H5, R7=OCH3;R3=4'-(2"-피리미딘일아미도설포닐)페닐아미도카르보닐,R4=R5=R8=H, R6=C2H5, R7=OCH3;R3=4'-(4", 6"-디메틸피리미디닐-2'-아미도설포닐)페닐아미도카르보닐,R4=R5=R8=H, R6=C2H5, R7=OCH3;R3=4'-(5",6"-디메톡시피리미디닐-4"-아미도설포닐)페닐아미도카르보닐, R4=R5=R8=H, R6=C2H5, R7=OCH3;R3=4'-(5"-CH3-이소옥사졸-3"-아미도설포닐)페닐아미도카르보닐,R4=R5=R8=H, R6= C2H5, R7=OCH3;R3=p-OCH3-페닐아미도카르보닐, R4=R5= R8=H, R6=C2H5, R7=OCH3;R3=p-SO3H-페닐아미도카르보닐, R4=R5= R8=H, R6=C2H5, R7=OCH3;R3=p-CO2H-페닐아미도카르보닐, R4=R5=R6=H, R7=OCH3, R8=CH3;R3=m-CO2H-페닐아미도카르보닐, R4=R5=R6=H, R7=OCH3, R8=CH3;R3=o-CO2H-페닐아미도카르보닐, R4=R5=R6=H, R7=OCH3, R8=CH3;R3=m-OH-p-CO2H-페닐아미도카르보닐, R4=R5=R6=H, R7=OCH3, R8=CH3;R3=m-CO2H-p-OH-페닐아미도카르보닐, R4=R5=R6=H, R7=OCH3 , R8=CH3;R3=o-CO2H-p-I-페닐아미도카르보닐, R4=R5=R6=H, R7=OCH3 , R8=CH3;R3=p-에톡시카르보페닐아미도카르보닐, R4=R5=R6=H, R7=OCH3, R8=CH3;R3=m-CF3-페닐아미도카르보닐, R4=R5=R6=H, R7=OCH3, R8=CH3;R3=m-CF3-4-NO2-페닐아미도카르보닐, R4=R5=R6=H, R7=OCH3, R8=CH3;R3=4'-아미도설포닐페닐아미도카르보닐, R4=R5=R6=H, R7=OCH3, R8=CH3;R3=4'-구아니디노설포닐페닐아미도카르보닐,R4=R5=R6=H, R7=OCH3, R8=CH3;R3=4'-(2"-티아졸아미도설포닐)페닐아미도카르보닐,R4=R5=R6=H, R7=OCH3, R8=CH3;R3=4'-(2"-피리미딘일아미도설포닐)페닐아미도카르보닐,R4=R5=R6=H, R7=OCH3, R8=CH3;R3=4'-(4", 6"-디메틸피리미디닐-2"-아미도설포닐)페닐아미도카르보닐,R4=R5= R6=H, R7=OCH3, R8=CH3;R3=4'-(5",6"-디메톡시피리미디닐-4"-아미도설포닐)페닐아미도카르보닐, R4=R5=R6=H, R7=OCH3, R8=CH3;R3=4'-(5"-CH3-이소옥사졸-3"-아미도설포닐)페닐아미도카르보닐,R4=R5=R6=H, R7=OCH3, R8=CH3;R3=p-OCH3-페닐아미도카르보닐, R4=R5=R6=H, R7=OCH3, R8= CH3;R3=p-SO3H-페닐아미도카르보닐, R4=R5= R6=H, R7=OCH3 R8= CH3;R3= p-CO2H-페닐아미도카르보닐, R4=R5=R6=H, R7=R8=OCH3;R3=m-OH-p-CO2H-페닐아미도카르보닐, R4=R5=R6=H, R7=R8=OCH3;R3=m-CO2H-p-OH-페닐아미도카르보닐, R4=R5=R6=H, R7=R8=OCH3;R3=p-에톡시카르보페닐아미도카르보닐, R4=R5=R6=H, R7=R8=OCH3;R3=m-CF3-페닐아미도카르보닐, R4=R5=R6=H, R7=R8=OCH3;R3=m-CF3-p-NO2-페닐아미도카르보닐, R4=R5=R6=H, R7=R8=OCH3;R3=m-HO2CCH2O-페닐아미도카르보닐, R4=R5=R6=H, R7=R8=OCH3;R3=4'-아미도설포닐페닐아미도카르보닐, R4=R5= R6=H, R7=R8=OCH3;R3=4'-구아니디노설포닐페닐아미도카르보닐, R4=R5= R6=H, R7=R8=OCH3;R3=p-CO2H-페닐아미도카르보닐, R4=R6=R8=H, R5=CH3, R7=OCH3;R3=m-CO2H-페닐아미도카르보닐, R4=R6=R8=H, R5=CH3, R7=OCH3;R3=o-CO2H-페닐아미도카르보닐, R4=R6=R8=H, R5=CH3, R7=OCH3;R3=o-OH-페닐아미도카르보닐, R4=R6=R8=H, R5=CH3, R7=OCH3;R3=m-OH-페닐아미도카르보닐, R4=R6=R8=H, R5=CH3, R7=OCH3;R3=p-OH-페닐아미도카르보닐, R4=R6=R8=H, R5=CH3, R7=OCH3;R3=m-OH-p-CO2H-페닐아미도카르보닐, R4=R6= R8=H, R5=CH3 R7=OCH3;R3=m-CO2H-p-OH-페닐아미도카르보닐, R4=R6=R8=H, R5=CH3, R7=OCH3;R3=p-에톡시카르보페닐아미도카르보닐, R4=R6=R8=H, R5=CH3, R7=OCH3;R3=m-CF3-페닐아미도카르보닐, R4=R6=R8=H, R5=CH3, R7=OCH3;R3=m-CF3-p-NO2-페닐아미도카르보닐, R4=R6=R8=H, R5=CH3, R7=OCH3;R3=4'-아미도설포닐페닐아미도카르보닐, R4=R6= R8=H, R5=CH3, R7=OCH3;R3=4'-구아니디노설포닐페닐아미도카르보닐, R4=R6=R8=H, R5=CH3, R7=OCH3;R3=4'-(2"-티아졸아미도설포닐)페닐아미도카르보닐,R4=R6=R8=H, R5=CH3, R7=OCH3;R3=4'-(2"-피리미딘일아미도설포닐)페닐아미도카르보닐,R4=R6=R8=H, R5=CH3, R7=OCH3;R3=4'-(4", 6"-디메틸피리미디닐-2"-아미도설포닐)페닐아미도카르보닐,R4=R6= R8=H, R5=CH3, R7=OCH3;R3=4'-(5",6"-디메톡시피리미디닐-4"-아미도설포닐)페닐아미도카르보닐, R4=R6= R8=H, R5=CH3, R7=OCH3;R3=4'-(5"-CH3-이소옥사졸-3"-아미도설포닐)페닐아미도카르보닐,R4=R6= R8=H, R5=CH3, R7=OCH3;R3=p-OCH3-페닐아미도카르보닐, R4=R6=R8=H, R5=CH3, R7=OCH3,;R3=p-CO2H-페닐아미도카르보닐, R4=R5=R8=H, R6=Cl, R7=OCH3;R3=m-OH-p-CO2H-페닐아미도카르보닐, R4=R5= R8=H, R6=Cl, R7=OCH3;R3=m-CO2H-p-OH-페닐아미도카르보닐, R4=R5=R8=H, R6=Cl, R7=OCH3;R3=p-에톡시카르보페닐아미도카르보닐, R4=R5=R8=H, R6=Cl, R7=OCH3;R3=m-CF3-페닐아미도카르보닐, R4=R5=R8=H, R6=Cl, R7 =OCH3;R3=4'-아미도서포닐페닐아미도카르보닐, R4=R5= R8=H, R6=Cl, R7=OCH3;R3='4-구아니디노설포닐페닐아미도카르보닐, R4=R5=R8=H, R6=Cl, R7=OCH3;R3=4'-(5", 6"-디메톡시피리미디닐-4"-아미도설포닐)페닐아미도카르보닐,R4=R5= R8=H, R6=Cl, R7=OCH3;R3=p-CO2H-페닐아미도카르보닐, R4=R5=R8=H, R6=Br, R7=OCH3;R3=o-CO2H-페닐아미도카르보닐, R4=R5=R8=H, R6=Br, R7=OCH3;R3=m-OH-p-CO2H-페닐아미도카르보닐, R4=R5=R8=H, R6=Br, R7= OCH3;R3=o-CO2H-p-I-페닐아미도카르보닐, R4=R5=R8=H, R6=Br, R7= OCH3;R3=p-에톡시카르보페닐아미도카르보닐, R4=R5=R8=H, R6=Br, R7=OCH3;R3=m-CF3-페닐아미도카르보닐, R4=R5=R8=H, R6=Br, R7 =OCH3;R3=4'-아미도서포닐페닐아미도카르보닐, R4=R5= R8=H, R6=Br, R7=OCH3;R3=p-OCH3-페닐아미도카르보닐, R4=R5=R8=H, R6=Br, R7=OCH3;R3=p-CO2H-페닐아미도카르보닐, R4=R5= R8=H, R6=n-Hex, R7=OCH3;R3=o-CO2H-페닐아미도카르보닐, R4=R5= R8=H, R6=n-Hex, R7=OCH3;R3=m-OH-p-CO2H-페닐아미도카르보닐, R4=R5=R8=H, R=Hex, R7= OCH3;R3=o-CO2H-p-I-페닐아미도카르보닐, R4=R5= R8=H, R6=n-Hex, R7=OCH3;R3=p-에톡시카르보페닐아미도카르보닐, R4=R5=R8=H, R6=Hex, R7=OCH3;R3= m-CF3-페닐아미도카르보닐, R4=R5=R8=H, R6=Hex, R7=OCH3;R3=4'-아미도설포닐페닐아미도카르보닐, R4=R5= R8=H, R6=Hex, R7=OCH3;R3=p-OCH3-페닐아미도카르보닐, R4=R5=R8=H, R6=Hex, R7 =OCH3;R3=p-CO2H-페닐아미도카르보닐, R4=R5=H, R6=NO2, R7=R8=OCH3;R3=m-CO2H-페닐아미도카르보닐, R4=R5=H, R6=NO2, R7=R8=OCH3;R3=p-OCH3-페닐아미도카르보닐, R4=R5=H, R6=NO2, R7=R8=OCH3;R3=m-OH-페닐아미도카르보닐, R4=R5=H, R6=NO2, R7=R8=OCH3;R3=o-OH-페닐아미도카르보닐, R4=R5=H, R6=NO2, R7=R8=OCH3;R3=p-에톡시카르보페닐아미도카르보닐, R4=R5=H, R6=NO2, R7=R8=OCH3;R3=m-OH-p-CO2H-페닐아미도카르보닐, R4=R5=H, R6=NO2, R7= R8= OCH3;R3=m-CO2H-p-OH-페닐아미도카르보닐, R4=R5=H, R6=NO2, R7=R8=OCH3;R3=m-CF3-페닐아미도카르보닐, R4=R5=H, R6=NO2, R7=R8=OCH3;R3=m-CF3-p-NO2-페닐아미도카르보닐, R4=R5=H, R6=NO2, R7=R8=OCH3;R3=4'-아미도설포닐페닐아미도카르보닐, R4=R5=H, R6=NO2, R7=R8=OCH3;R3=4'-구아니디노설포닐페닐아미도카르보닐, R4=R5=H, R6=NO2, R7=R8=OCH3;R3=4'-(2"-피리미딘일아미도설포닐)페닐아미도카르보닐,R4=R5=H, R6=NO2, R7=R8=OCH3;R3=4'-(5",6"-디메톡시피리미디닐-4"-아미도설포닐)페닐아미도카르보닐, R4=R5=H, R6=NO2, R7=R8=OCH3;R3=4'-(2"-티아졸아미도설포닐)페닐아미도카르보닐,R4=R5=H, R6=NO2, R7=R8=OCH3;R3=p-CO2H-페닐아미도카르보닐, R4=R5=H, R6=C2H5, R7=OH, R8=NO2;R3=p-OCH3-페닐아미도카르보닐, R4=R5=H, R6=C2H5, R7=OH, R8=NO2;R3=m-OH-페닐아미도카르보닐, R4=R5=H, R6=C2H5, R7=OH, R8=NO2;R3=o-OH-페닐아미도카르보닐, R4=R5=H, R6=C2H5, R7=OH, R8=NO2;R3=p-에톡시카르보페닐아미도카르보닐, R4=R5=H, R6=C2H5, R7=OH, R8=NO2;R3=m-OH-p-CO2H-페닐아미도카르보닐,R4=R5=H, R6=C2H5, R7=OH, R8=NO2;R3=m-CO2H-p-OH-페닐아미도카르보닐, R4=R5=H, R6=C2H5, R7=OH, R8=NO2;R3=m-CF3- 페닐아미도카르보닐, R4=R5=H, R6=C2H5, R7=OH, R8=NO2;R3=4'-아미도설포닐페닐아미도카르보닐,R4=R5=H, R6=C2H5, R7=OH, R8=NO2;R3=4'-구아니디노설포닐페닐아미도카르보닐,R4=R5=H, R6=C2H5, R7=OH, R8=NO2;R3=4'-(2"-티아졸아미도설포닐)페닐아미도카르보닐,R4=R5=H, R6=C2H5, R7=OH, R8=NO2;R3=p-CO2H-페닐아미도카르보닐, R4=R5=H, R6=C2H5, R7=OCH3, R8=NO2;R3=p-OH-페닐아미도카르보닐, R4=R5=H, R6=C2H5, R7=OCH3, R8=NO2;R3=p-OCH3-페닐아미도카르보닐, R4=R5=H, R6=C2H5, R7=OCH3, R8=NO2;R3=p-에톡시카르보페닐아미도카르보닐, R4=R5=H, R6=C2H5, R7=OH, R8=NO2;R3=4'-구아니디노설포닐페닐아미도카르보닐,R4=R5=H, R6=C2H5, R7=OCH3, R8=NO2;R3=p-CO2H-페닐아미도카르보닐, R4=R5=H, R6=NO2, R7=OH, R8=CH3;R3=o-CO2H-페닐아미도카르보닐, R4=R5=H, R6=NO2, R7=OH, R8=CH3;R3=p-OH-페닐아미도카르보닐, R4=R5=H, R6=NO2, R7=OH, R8=CH3;R3=m-OH-페닐아미도카르보닐, R4=R5=H, R6=NO2, R7=OH, R8=CH3;R3=o-OH-페닐아미도카르보닐, R4=R5=H, R6=NO2, R7=OH, R8=CH3;R3=p-OCH3-페닐아미도카르보닐, R4=R5=H, R6=NO2, R7=OH, R8=CH3;R3=p-에톡시카르보페닐아미도카르보닐, R4=R5=H, R6=NO2, R7=OH, R8=CH3;R3=m-OH-p-CO2H-페닐아미도카르보닐, R4=R5=H, R6=NO2, R7=OH, R8=CH3;R3=m-CO2H-p-OH-페닐아미도카르보닐, R4=R5=H, R6=NO2, R7=OH, R8=CH3R3=m-CF3-페닐아미도카르보닐, R4=R5=H, R6=NO2, R7=OH, R8=CH3R3=m-CF3-p-NO2-페닐아미도카르보닐, R4=R5=H, R6=NO2, R7=OH, R8=CH3R3=4'-아미도설포닐페닐아미도카르보닐, R4=R5=H, R6=NO2, R7=OH, R8=CH3;R3=4'-구아니디노설포닐페닐아미도카르보닐,R4=R5=H, R6=NO2, R7=OH, R8=CH3;R3=4'-(2"-피리미딘일아미도설포닐)페닐아미도카르보닐,R4=R5=H, R6=NO2, R7=OH, R8=CH3;R3=4'-(5", 6"-디메톡시피리미디닐-4"-아미도설포닐)페닐아미도카르보닐, R4=R5= H, R6=NO2, R7=OH, R8=CH3;R3=4'-(2"-티아졸아미도설포닐)페닐아미도카르보닐,R4=R5=H, R6=NO2, R7=OH, R8=CH3;R3=o-CO2H-p-I-페닐아미도카르보닐, R4=R5=H, R6=NO2, R7=OH, R8=CH3;R3=p-CO2H-페닐아미도카르보닐, R4=R5=H, R6=NO2, R7=OCH3, R8=CH3;R3=m-CO2H-페닐아미도카르보닐, R4=R5=H, R6=NO2, R7=OCH3, R8=CH3;R3=o-CO2H-페닐아미도카르보닐, R4=R5=H, R6=NO2, R7=OCH3, R8=CH3;R3=p-OH-페닐아미도카르보닐, R4=R5=H, R6=NO2, R7=OCH3, R8=CH3;R3=m-OH-페닐아미도카르보닐, R4=R5=H, R6=NO2, R7=OCH3, R8=CH3;R3=o-OH-페닐아미도카르보닐, R4=R5=H, R6=NO2, R7=OCH3, R8=CH3;R3=p-OCH3-페닐아미도카르보닐, R4=R5=H, R6=NO2, R7=OCH3, R8=CH3;R3=p-에톡시카르보페닐아미도카르보닐, R4=R5=H, R6=NO2, R7=OCH3, R8=CH3;R3=m-OH-p-CO2H-페닐아미도카르보닐,R4=R5=H, R6=NO2, R7=OCH3, R8=CH3;R3=m-CF3-페닐아미도카르보닐, R4=R5=H, R6=NO2, R7=OCH3, R8=CH3;R3=m-CF3-p-NO2-페닐아미도카르보닐, R4=R5=H, R6=NO2, R7=OCH3, R8=CH3;R3=4'-구아니디노설포닐페닐아미도카르보닐,R4=R5=H, R6=NO2, R7=OCH3, R8=CH3;R3=4'-아미도서포닐페닐아미도카르보닐,R4=R5=H, R6=NO2, R7=OCH3, R8=CH3;R3=4'-(5", 6"-디메톡시피리미디닐-4"-아미도설포닐)페닐아미도카르보닐, R4=R5=H, R6=NO2, R7=OCH3, R8=CH3;R3=4'-(2"-티아졸아미도설포닐)페닐아미도카르보닐,R4=R5=H, R6=NO2, R7=OCH3, R8=CH3;R3=4'-(2"-피리미딘일아미도설포닐)페닐아미도카르보닐,R4=R5=H, R6=NO2, R7=OCH3, R8=CH3;R3=p-CO2H-페닐아미도카르보닐, R4=R5=H, R6= R8=NO2, R7=OH;R3=p-OH-페닐아미도카르보닐, R4=R5=H, R6= R8=NO2, R7=OH;R3=m-OH-페닐아미도카르보닐, R4=R5=H, R6= R8=NO2, R7=OH;R3=o-OH-페닐아미도카르보닐, R4=R5=H, R6= R8=NO2, R7=OH;R3=p-OCH3-페닐아미도카르보닐, R4=R5=H, R6= R8=NO2, R7=OH;R3=p-에톡시카르보페닐아미도카르보닐, R4=R5=H, R6=R8=NO2, R7=OH;R3=CF3-페닐아미도카르보닐, R4=R5=H, R6= R8=NO2, R7=OH;R3=4'-아미도설포닐페닐아미도카르보닐, R4=R5=H, R6= R8=NO2, R7=OH;R3=4'-구아니디노설포닐페닐아미도카르보닐, R4=R5=H, R6= R8=NO2, R7=OH;R3=4'-(2"-피리미딘일아미도설포닐)페닐아미도카르보닐,R4=R5=H, R6=R8=NO2, R7=OH;R3=4'-(5",6"-디메톡시피리미디닐-4"-아미도설포닐)페닐아미도카르보닐,R4=R5=H, R6= R8=NO2, R7=OH;R3=4'-(2"-티아졸아미도설포닐)페닐아미도카르보닐, R4=R5=H, R6=R8=NO2, R7=OH;R3=o-CO2H-페닐아미도카르보닐, R4=R5=H, R6= R8=NO2, R7=OH;R3=p-OH-페닐아미도카르보닐, R4=R5=H, R6= R8=NO2, R7=OCH3;R3=p-에톡시카르보페닐아미도카르보닐, R4=R5=H, R6=R8=NO2, R7=OCH3;R3=p-OCH3-페닐아미도카르보닐, R4=R5=H, R6=R8=NO2, R7=OCH3;R3=p-OCH3-페닐아미도카르보닐, R4=R5=H, R6=Cl, R7=OH, R8=NO2;R3=4'-구아니디노설포닐페닐아미도카르보닐, R4=R5=H, R6=Cl, R7=OH, R8=NO2;R3=m-OH-pCO2H-페닐아미도카르보닐,R4=H, R5=CH3, R7=OH, R6=Cl, R8=NO2;R3= p-CO2H-페닐아미도카르보닐, R4=H, R5=CH3, R7=OH, R6=R8=NO2;R3=m-CO2H-페닐아미도카르보닐, R4=H, R5=CH3, R7=OH, R6=R8=NO2;R3=o-CO2H-페닐아미도카르보닐, R4=H, R5=CH3, R7=OH, R6=R8=NO2;R3= p-OCH3-페닐아미도카르보닐, R4=H, R5=CH3, R7=OH, R6=R8=NO2;R3=p-에톡시카르보페닐아미도카르보닐, R4=H, R5=CH3, R7=OH, R6=R8=NO2;R3=p-아미도설포닐페닐아미도카르보닐,R4=H, R5=CH3, R7=OH, R6=R8=NO2;R3=p-구아니디노설포닐페닐아미도카르보닐,R4=H, R5=CH3, R7=OH, R6=R8=NO2;R3= 4'-(2"-피리미딘일아미도설포닐)페닐아미도카르보닐,R4=H, R5=CH3, R7=OH, R6=R8=NO2;R3= 4'-(2"-티아졸아미도설포닐)페닐아미도카르보닐,R4=H, R5=CH3, R7=OH, R6=R8=NO2;R3=4'--(4", 6"-디메틸피리미디닐-2"-아미도설포닐)페닐아미도카르보닐,R4=H, R5=CH3, R7=OH, R6=R8=NO2;R3=CONH(CH)3COOH, R4=R5=R6=R8=H, R7=OCH3;R3=CO2C2H5, R4=R5=H, R6=NO2, R7=R8=OCH3;R3=CO2H, R4=R5=H, R6=NO2, R7=R8=OCH3;R3=CO2C2H5, R4=R5=H, R6=NO2, R7=OH, R8=CH3;R3=CO2H, R4=R5=H, R6=NO2, R7=OH, R8=CH3;R3=CO2C2H5, R4=R5=H, R6=NH2, R7=OH, R8=CH3;R3=CO2H, R4=R5=H, R6=NO2, R7=OCH3, R8=CH3;R3=CO2C2H5, R4=R5=H, R6=C2H5, R7=OH, R8=NO2;R3=CO2H, R4=R5=H, R6=C2H5, R7=OH, R8=NO2;R3=CO2C2H5, R4=R5=H, R6=C2H5, R7=OCH3, R8=NO2;R3=CO2H, R4=R5=H, R6=C2H5, R7=OCH3, R8=NO2;R3=CO2C2H5, R4=R5=H, R6= R8=NO2, R7=OH;R3=CO2H, R4=R5=H, R6= R8=NO2, R7=OH;R3=CO2C2H5, R4=R5=H, R6=R8=NO2, R7=OCH3;R3=CO2H, R4=R5=H, R6= R8=NO2, R7=OCH3;R3=CO2C2H5, R4=R5=H, R6=Cl, R7=OH, R8=NO2;R3=CO2H, R4=R5=H, R6=Cl, R7=OH, R8=NO2;R3=CO2H, R4=H, R5=CH3, R6=R8=NO2, R7=OH;R3=CO2C2H5, R4=H, R5=CH3, R6=R8=NO2, R7=OH;
- 제1항에 있어서, 상기 화합물은 약제학적으로 허용가능한 염 및 염의 수화물, 에스테르, 혹은 약물 전구체를 포함하는 것을 특징으로 하는 화합물.
- 치환된 3-카르복시-, 4-카르복시-, 6-카르복시쿠마린, 또는 치환된 7-카르복시메틸렌옥시쿠마린 유도체와 이와 상응되는 치환된 아민 또는 히드라진을 축합반응하여 제1항 내지 제6항중 어느 한 항에 따른 화합물을 제조하는 방법.
- 제7항에 있어서, 상기 제조방법이 치환된 3-카르복시-, 4-카르복시-, 6-카르복시-, 혹은 7-카르복시메틸렌옥시코마린 유도체와 상응되는 치환된 히드라진을 축합반응함으로써 얻어진 히드라지드를 고리화하여 헤테로시클릭 유도체를 형성하는 것을 특징으로 하는 방법.
- 제7항 및 제8항에 있어서, 상기 아미드화(amidation) 반응을 하기 위한 반응물은 삼염화인, 옥시염화인, 오염화인, 티오닐 클로라이드 1,3-디시클로헥실카르보이미드(DCC), 디피리딜 카르보네이트(2-DPC), l,3-디이소프로필 카르보디이미드(DIPC), 또는 1-(3-디메틸아미노프로필)-3-에틸카르보이미드(EDCI)를 포함하고; 사용되는 촉매제는 3급 아민, 피리딘, 4-디메틸아미노피리딘 및 4-피롤알킬피리딘으로 이루어진 군에서 선택된 것이고; 유기 용매는 디메틸설폭시드,디클로로메탄, 톨루엔, 에틸렌글리콜 디메틸에테르, 1,2-디클로로에탄, 테트로히드로퓨란 또는 N,N-디메틸포름아미드(DMF)를 포함하는 것을 특징으로 하는 방법.
- 제1항 내지 제6항중 어느 한 항에 따른 화합물의 약제학적 유효 투여량 및 약제학적으로 허용가능한 담체를 포함하는 것을 특징으로 하는 약제학적 조성물.
- 제10항에 있어서, 상기의 약제학적 조성물은 정제, 캅셀제, 환제, 주사제, 서방성(sustained release)제제, 방출 제어형 제제 또는 표적지향형 제제(targeted preparation) 및 각종 미세 입자 약물 전달 시스템인 것을 특징으로 하는 조성물.
- TGF-β1(변형 성장 인자 β1) 억제제를 제조하기 위한 제1항 내지 제6항중 어느 한 항에 따른 용도.
- 안기오텐신 II(AngII) 수용체 전환 효소의 길항제를 제조하기 위한 제1항 내지 제6항중 어느 한 항에 따른 용도.
- 만성 신장질환 치료용 약물을 제조하기 위한 제1항 내지 제6항중 어느 한 항에 따른 용도.
- 심장뇌혈관계 질환 치료용 약물을 제조하기 위한 제1항 내지 제6항중 어느 한 항에 따른 용도.
- 인슐린 비의존형 당뇨병 치료용 약물을 제조하기 위한 제1항 내지 제6항중 어느 한 항에 따른 용도.
- 제l5항에 있어서, 상기 심장뇌혈관계 질환이 고혈압, 뇌 및 관상동맥 색전증, 심근경색, 뇌혈관계 중풍, 뇌졸증 및 이들의 휴유증인 것을 특징으로 하는 용도.
- 종양(tumor) 및 전암성 장애(pre-cancerous lesion)의 치료 또는 예방용 약물을 제조하기 위한 제1항 내지 제6항중 어느 한 항에 따른 용도.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN02155525.7 | 2002-12-05 | ||
CNA021555257A CN1506359A (zh) | 2002-12-05 | 2002-12-05 | 新的香豆素酰胺衍生物及其制法和其药物组合物与用途 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020107013277A Division KR20100087748A (ko) | 2002-12-05 | 2003-12-05 | 신규한 쿠마린 아미드 유도체와 그 제조방법, 약제학적 조성물과 용도 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20050084184A true KR20050084184A (ko) | 2005-08-26 |
KR101000395B1 KR101000395B1 (ko) | 2010-12-13 |
Family
ID=32400079
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020107013277A KR20100087748A (ko) | 2002-12-05 | 2003-12-05 | 신규한 쿠마린 아미드 유도체와 그 제조방법, 약제학적 조성물과 용도 |
KR1020057010241A KR101000395B1 (ko) | 2002-12-05 | 2003-12-05 | 신규한 쿠마린 아미드 유도체와 그 제조방법, 약제학적조성물과 용도 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020107013277A KR20100087748A (ko) | 2002-12-05 | 2003-12-05 | 신규한 쿠마린 아미드 유도체와 그 제조방법, 약제학적 조성물과 용도 |
Country Status (11)
Country | Link |
---|---|
US (1) | US8338401B2 (ko) |
EP (2) | EP1570846A4 (ko) |
JP (1) | JP4722487B2 (ko) |
KR (2) | KR20100087748A (ko) |
CN (2) | CN1506359A (ko) |
AU (1) | AU2003289641A1 (ko) |
BR (2) | BRPI0316595B1 (ko) |
CA (1) | CA2508573C (ko) |
IL (1) | IL168959A (ko) |
RU (1) | RU2361870C2 (ko) |
WO (1) | WO2004050082A1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101133246B1 (ko) * | 2010-02-24 | 2012-04-05 | 원광대학교산학협력단 | 신규한 코마린 유도체, 이의 제조방법 및 상기 코마린 유도체를 포함하는 형광 면역측정용 키트 |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0319126D0 (en) * | 2003-08-14 | 2003-09-17 | Smithkline Beecham Corp | Chemical compounds |
WO2006070984A1 (en) * | 2004-12-31 | 2006-07-06 | Sk Chemicals, Co., Ltd. | Novel benzopyran derivatives having inhibitory activities against liver fibrosis and cirrhosis and their pharmaceutical uses |
BRPI0707989A2 (pt) | 2006-02-21 | 2011-05-17 | Toyama Chemical Co Ltd | métodos para preparar um derivado de ácido fenilpropiÈnico, um derivado de benzofenona, um derivado de 6-metil-1, 2-benzisoxazol-3(2h) -ona e ácido 2-oxo-2h-cromeno carboxìlico, derivado de 6-(halometil) -1, 2-benzisoxazol-3(2h) -ona, e, derivado de benzofenona ou um sal do mesmo |
CN1810795A (zh) * | 2006-03-03 | 2006-08-02 | 中国科学院上海药物研究所 | 一类新的苯并吡喃化合物、其制备方法和用途 |
US20070232660A1 (en) * | 2006-04-04 | 2007-10-04 | Allergan, Inc. | Therapeutic and delivery methods of prostaglandin ep4 agonists |
GB0607389D0 (en) * | 2006-04-12 | 2006-05-24 | Novartis Ag | Organic compounds |
WO2007124617A1 (fr) * | 2006-04-28 | 2007-11-08 | Institute Of Mataria Medica, Chinese Academy Of Medical Sciences | Dérivés de coumarine, leurs procédés de préparation, compositions pharmaceutiques et utilisations |
WO2008006051A2 (en) * | 2006-07-07 | 2008-01-10 | Govek Steven P | Bicyclic heteroaryl inhibitors of pde4 |
CA2675471A1 (en) * | 2007-02-02 | 2008-08-07 | Novartis Ag | Chromene s1p1 receptor antagonist |
WO2008128100A1 (en) * | 2007-04-13 | 2008-10-23 | The Regents Of The University Of California | Small-molecule inhibitors of the androgen receptor |
CN101368003B (zh) * | 2007-08-15 | 2011-09-14 | 中国科学院理化技术研究所 | 吡唑啉吡啶并香豆素荧光染料衍生物及其合成方法和用途 |
KR101093930B1 (ko) * | 2007-09-13 | 2011-12-13 | 경북대학교병원 | 스코파론의 신규 용도 |
WO2009100250A1 (en) | 2008-02-05 | 2009-08-13 | Fibrogen, Inc. | Chromene derivatives and use thereof as hif hydroxylase activity inhibitors |
CN101525497B (zh) * | 2008-03-06 | 2012-07-04 | 中国科学院理化技术研究所 | 吡唑啉吡啶并苯并香豆素荧光染料衍生物及其合成方法和用途 |
WO2009132307A1 (en) * | 2008-04-24 | 2009-10-29 | The Regents Of The University Of California | Small-molecule inhibitors of the androgen receptor |
EP2370422B1 (en) | 2008-11-14 | 2019-06-05 | Fibrogen, Inc. | Thiochromene derivatives as hif hydroxylase inhibitors |
CN103788044B (zh) * | 2008-11-28 | 2016-09-14 | 中国医学科学院药物研究所 | 硝克柳胺化合物晶i型、其制法和其药物组合物与用途 |
CN103833713B (zh) * | 2008-11-28 | 2016-02-03 | 中国医学科学院药物研究所 | 硝克柳胺化合物晶iii型、其制法和其药物组合物与用途 |
CN101780070B (zh) * | 2009-01-16 | 2012-08-22 | 广州康臣药物研究有限公司 | 一种治疗糖尿病肾病的药物组合物及其制备方法 |
CN101643463B (zh) * | 2009-09-03 | 2011-12-28 | 祁刚 | 6-甲基香豆素-7-磺酰脲类化合物及其合成方法 |
CN105153188B (zh) * | 2009-10-22 | 2018-06-01 | 法博太科制药有限公司 | 抗纤维化剂的稠环类似物 |
CA2778611A1 (en) * | 2009-10-23 | 2011-04-28 | Allergan, Inc. | Coumarin compounds as receptor modulators with therapeutic utility |
CN102241891B (zh) * | 2010-05-14 | 2013-08-21 | 中国科学院理化技术研究所 | 吡唑并吡啶类香豆素染料衍生物及其合成方法和用途 |
CN101985449B (zh) * | 2010-09-28 | 2012-08-22 | 中山大学 | 一种香豆素衍生物及其制备方法和作为抗癌药物的用途 |
CN102558125A (zh) * | 2012-01-10 | 2012-07-11 | 中国药科大学 | 3-乙酰氨基-7-羟基-6-甲氧基香豆素衍生物、制备方法及其用途 |
CN102584762A (zh) * | 2012-01-10 | 2012-07-18 | 中国药科大学 | 东莨菪素衍生物、制备方法及其用途 |
WO2014028025A1 (en) * | 2012-08-16 | 2014-02-20 | University Of Southern California | Compositions and methods for treating myotonic dystrophy type 1 |
RU2549357C2 (ru) * | 2013-06-04 | 2015-04-27 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Пермский государственный национальный исследовательский университет" | Способ получения метил 1-[3-(циклогексилкарбамоил)-2-оксохроман-4-ил] циклопентакарбоксилата, проявляющего анальгетическую активность |
CN103408530B (zh) * | 2013-08-26 | 2015-05-27 | 中国人民解放军第三军医大学 | 具有生物活性的香豆素骨架多环化合物及制备方法和用途 |
US10364230B2 (en) | 2014-11-05 | 2019-07-30 | Altay Therapeutics, Inc. | Chromene-2 derivatives and use thereof in the treatment of fibrosis |
CN105601624B (zh) * | 2016-02-17 | 2018-05-22 | 南京双科医药开发有限公司 | 一种1,2,4-三嗪-香豆素型化合物及其制法和用途 |
SG11201907139UA (en) | 2017-02-03 | 2019-09-27 | Certa Therapeutics Pty Ltd | Anti-fibrotic compounds |
CN107868069A (zh) * | 2017-10-31 | 2018-04-03 | 山东新华制药股份有限公司 | 7‑羟基‑8‑甲基‑6‑硝基‑2‑氧‑2h‑苯并吡喃‑3‑羧酸的制备工艺 |
CN108218854B (zh) * | 2017-12-29 | 2020-04-10 | 厦门大学 | 苯丙吡喃-2-酮类化合物作为jmjd6抑制剂及用途 |
CN109232517B (zh) * | 2018-10-16 | 2020-06-12 | 郑州大学第一附属医院 | 一组磺酰香豆素类衍生物及其在制备抗肿瘤药物中的应用 |
WO2020130120A1 (ja) * | 2018-12-20 | 2020-06-25 | 学校法人京都薬科大学 | 癌転移抑制剤 |
CN110156761B (zh) * | 2019-06-18 | 2022-08-09 | 郑州大学 | 含香豆素-联苯骨架化合物、制备方法及其应用 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2683720A (en) * | 1949-12-15 | 1954-07-13 | Endo Products Inc | Process for the preparation of 6-nitro-coumarin-3-carboxylic acid |
FR7513M (ko) | 1967-11-20 | 1969-12-15 | ||
GB1388590A (en) | 1972-09-06 | 1975-03-26 | Hickson & Welch Ltd | 3-oxadiazolyl-coumarins and their use as brightening agents |
WO1989007939A2 (en) * | 1988-03-01 | 1989-09-08 | The Upjohn Company | Coumarins to inhibit reverse transcriptase in humans |
JP2802097B2 (ja) | 1989-05-31 | 1998-09-21 | 財団法人微生物化学研究会 | 新規な制癌抗生物質mi43―37f11及びその製造法 |
HUT63843A (en) * | 1992-02-13 | 1993-10-28 | Biosignal Kutato Fejlesztoe Kf | Process for producing new kumarin derivatives and their analogs inhibiting mammal cell proliferation and tumour growth, as well as pharmaceutical comkpositions comprising such compounds |
JPH06145164A (ja) * | 1992-11-04 | 1994-05-24 | Mitsui Toatsu Chem Inc | 紫外線吸収剤およびそれに適したベンゾピラン誘導体ならびに該紫外線吸収剤を含有してなる熱可塑性樹脂組成物および成形体 |
JP3556970B2 (ja) * | 1993-07-22 | 2004-08-25 | 三井化学株式会社 | ベンゾピラン化合物及びその用途 |
JP3603327B2 (ja) | 1994-04-12 | 2004-12-22 | 大日本インキ化学工業株式会社 | 糖尿病治療剤 |
US6090958A (en) * | 1995-03-31 | 2000-07-18 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
US5716982A (en) * | 1995-06-07 | 1998-02-10 | Institute Of Materia Medica, An Institute Of The Chinese Academy Of Medical Sciences | Retinoids and methods of use of same |
WO1997018808A1 (en) * | 1995-11-17 | 1997-05-29 | Pharmacia & Upjohn Company | 4-hydroxycoumarin-3-carboxamides for the treatment of diabetes mellitus |
JP3885900B2 (ja) | 1996-03-22 | 2007-02-28 | 大日本インキ化学工業株式会社 | ベンゾピラン誘導体及びそれを有効成分とする心臓疾患治療剤 |
IT1289238B1 (it) | 1996-12-10 | 1998-09-29 | Bio S S P A Ora Bio S S R L | Composizioni farmaceutiche per il trattamento di infezioni virali comprendenti una 4 arilcumarina |
EP1015008B1 (en) * | 1997-02-07 | 2015-08-05 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
US5773647A (en) * | 1997-02-07 | 1998-06-30 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
FR2763944B1 (fr) * | 1997-06-03 | 2000-12-15 | Centre Nat Rech Scient | Nouveaux derives de coumarines, leurs procedes de preparation et leur application comme medicaments en tant qu'inhibiteurs de proteases |
CN1108297C (zh) * | 1997-07-31 | 2003-05-14 | 中国医学科学院药物研究所 | 维甲酰香豆素类化合物及其制备方法和含该化合物的药物组合物 |
GB9722600D0 (en) | 1997-10-24 | 1997-12-24 | Bio Monde Holdings Internation | Pharmaceutical compositon |
JP2000218940A (ja) * | 1999-02-02 | 2000-08-08 | Mitsui Chemicals Inc | 光記録媒体 |
NZ517781A (en) | 1999-09-14 | 2004-01-30 | Biogen Inc | Therapies for chronic renal failure using one or more integrin antagonists |
HN2001000008A (es) * | 2000-01-21 | 2003-12-11 | Inc Agouron Pharmaceuticals | Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo |
FI20001593A (fi) * | 2000-07-03 | 2002-01-04 | Orion Yhtymo Oyj | Comt-entsyymiõ inhiboivaa aktiivisuutta omaavia kumariinijohdannaisia |
CA2445515A1 (en) * | 2001-05-04 | 2002-11-04 | Paratek Pharmaceuticals, Inc. | Transcription factor modulating compounds and methods of use thereof |
JP4986423B2 (ja) | 2005-08-03 | 2012-07-25 | 日東電工株式会社 | 剥離処理基材及びその製造方法 |
-
2002
- 2002-12-05 CN CNA021555257A patent/CN1506359A/zh active Pending
-
2003
- 2003-12-05 US US10/537,711 patent/US8338401B2/en not_active Expired - Fee Related
- 2003-12-05 JP JP2004555972A patent/JP4722487B2/ja not_active Expired - Fee Related
- 2003-12-05 AU AU2003289641A patent/AU2003289641A1/en not_active Abandoned
- 2003-12-05 RU RU2005121137/04A patent/RU2361870C2/ru not_active IP Right Cessation
- 2003-12-05 BR BRPI0316595A patent/BRPI0316595B1/pt unknown
- 2003-12-05 KR KR1020107013277A patent/KR20100087748A/ko not_active Application Discontinuation
- 2003-12-05 EP EP03776786A patent/EP1570846A4/en not_active Withdrawn
- 2003-12-05 WO PCT/CN2003/001046 patent/WO2004050082A1/zh active Application Filing
- 2003-12-05 CN CNB200380109516XA patent/CN100488504C/zh not_active Expired - Lifetime
- 2003-12-05 EP EP10190730.1A patent/EP2295053B8/en not_active Expired - Lifetime
- 2003-12-05 BR BR0316595-7A patent/BR0316595A/pt not_active IP Right Cessation
- 2003-12-05 CA CA2508573A patent/CA2508573C/en not_active Expired - Fee Related
- 2003-12-05 KR KR1020057010241A patent/KR101000395B1/ko active IP Right Grant
-
2005
- 2005-06-02 IL IL168959A patent/IL168959A/en active IP Right Grant
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101133246B1 (ko) * | 2010-02-24 | 2012-04-05 | 원광대학교산학협력단 | 신규한 코마린 유도체, 이의 제조방법 및 상기 코마린 유도체를 포함하는 형광 면역측정용 키트 |
Also Published As
Publication number | Publication date |
---|---|
CN1829506A (zh) | 2006-09-06 |
JP2006512328A (ja) | 2006-04-13 |
US8338401B2 (en) | 2012-12-25 |
EP2295053B1 (en) | 2016-10-19 |
EP2295053A1 (en) | 2011-03-16 |
BRPI0316595B1 (pt) | 2018-12-26 |
CN1506359A (zh) | 2004-06-23 |
RU2005121137A (ru) | 2006-01-20 |
AU2003289641A1 (en) | 2004-06-23 |
CN100488504C (zh) | 2009-05-20 |
CA2508573C (en) | 2012-09-11 |
EP1570846A4 (en) | 2008-02-20 |
IL168959A (en) | 2013-08-29 |
EP2295053B8 (en) | 2018-03-28 |
RU2361870C2 (ru) | 2009-07-20 |
EP1570846A1 (en) | 2005-09-07 |
WO2004050082A1 (fr) | 2004-06-17 |
KR20100087748A (ko) | 2010-08-05 |
US20060148834A1 (en) | 2006-07-06 |
CA2508573A1 (en) | 2004-06-17 |
BR0316595A (pt) | 2005-10-04 |
JP4722487B2 (ja) | 2011-07-13 |
KR101000395B1 (ko) | 2010-12-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101000395B1 (ko) | 신규한 쿠마린 아미드 유도체와 그 제조방법, 약제학적조성물과 용도 | |
CA2682393C (en) | 5-membered heterocyclic derivative and use thereof for medical purposes | |
JP2002308875A (ja) | エンドセリンの活性を調節するスルホンアミドおよびそれらの誘導体 | |
CN101835752A (zh) | 用于治疗癌症和银屑病的杂环酰胺 | |
JPH06507625A (ja) | アンギオテンシンiiアンタゴニストとしての酸官能基を有する置換ピリミジノン | |
CN106831725B (zh) | 含二氢吲哚啉及类似结构的喹唑啉类化合物及其应用 | |
DE102006050513A1 (de) | Substitiuierte Dihydropyrazolone und ihre Verwendung | |
CN101484421A (zh) | 作为parp抑制剂的2-氧基苯甲酰胺衍生物 | |
CA2626029A1 (en) | Pharmaceutical gallium compositions and methods | |
MX2011007064A (es) | Compuestos de quinazolina substituidos. | |
WO2020233618A1 (zh) | 一类细胞程序性坏死抑制剂及其制备方法和用途 | |
CN102108078B (zh) | 1,4-取代酞嗪类化合物及其制备方法和用途 | |
AU2219599A (en) | Platelet adp receptor inhibitors | |
KR20080081325A (ko) | 신규한, 시클릭 치환 푸로피리미딘 유도체 및 심혈관질환을 치료하기 위한 그의 용도 | |
CN110317173B (zh) | 用作fgfr不可逆抑制剂的酰胺基吡唑类化合物 | |
US5180717A (en) | Bivalent ligands effective for blocking ACAT enzyme for lowering plasma triglycerides and for elevating HDL cholesterol | |
JPH0692410B2 (ja) | 新規なベンゾフロキノリン誘導体 | |
US5070088A (en) | Pyranyl quinoline calcium channel blockers | |
US6699857B1 (en) | Tetrahydroquinolinyl 6-methyldihydrothiadiazinone derivatives and use thereof | |
KR20050044853A (ko) | 카르복실산 유도체 화합물 및 이 화합물을 유효성분으로서함유하는 약제 | |
KR101992356B1 (ko) | 피리딘 유도체 또는 이의 약제학적 허용가능한 염 및 이를 유효성분으로 함유하는 약학 조성물 | |
CN109824574B (zh) | 吲哚-3-甲酰胺类化合物及其应用 | |
CN102603755B (zh) | 一类具有协同氟康唑抗耐药真菌作用的化合物 | |
CA1132558A (en) | Quinazoline antihypertensives | |
WO2002096889A1 (fr) | Compose de quinazolinone et son procede de preparation ainsi que son utilisation dans la preparation d'un medicament anticancereux |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
J201 | Request for trial against refusal decision | ||
A107 | Divisional application of patent | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
B701 | Decision to grant | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20131118 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20141114 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20151126 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20161121 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20171124 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20181116 Year of fee payment: 9 |